X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (176) 176
index medicus (170) 170
cardiac & cardiovascular systems (132) 132
female (124) 124
heart failure (120) 120
male (120) 120
cardiovascular (107) 107
middle aged (101) 101
aged (86) 86
mortality (86) 86
prognosis (85) 85
biomarkers - blood (84) 84
biomarkers (76) 76
abridged index medicus (75) 75
natriuretic peptide, brain - blood (61) 61
natriuretic peptides (56) 56
heart failure - blood (53) 53
peptide fragments - blood (50) 50
cardiovascular disease (48) 48
diagnosis (48) 48
cardiology (46) 46
heart attacks (45) 45
cardiac patients (41) 41
risk factors (40) 40
heart failure - diagnosis (39) 39
acute disease (34) 34
predictive value of tests (34) 34
internal medicine (33) 33
peptides (33) 33
risk (33) 33
myocardial-infarction (32) 32
patients (32) 32
acute coronary syndromes (31) 31
adult (31) 31
medical laboratory technology (31) 31
natriuretic peptide (31) 31
treatment outcome (31) 31
management (30) 30
prospective studies (30) 30
studies (28) 28
analysis (27) 27
heart (27) 27
interleukin-1 receptor-like 1 protein (27) 27
follow-up studies (25) 25
outcomes (25) 25
aged, 80 and over (24) 24
heart diseases (24) 24
brain natriuretic peptide (23) 23
heart failure - therapy (21) 21
prognostic value (21) 21
receptors, cell surface - blood (21) 21
research (21) 21
troponin t - blood (21) 21
cardiology and cardiovascular medicine (20) 20
drug therapy (20) 20
health aspects (20) 20
heart failure - physiopathology (20) 20
medical colleges (20) 20
soluble st2 (20) 20
time factors (20) 20
cohort studies (19) 19
diabetes (19) 19
echocardiography (19) 19
heart-failure (19) 19
risk assessment (19) 19
age (18) 18
association (18) 18
cardiovascular diseases (18) 18
heart failure - mortality (18) 18
risk stratification (18) 18
severity of illness index (18) 18
care and treatment (17) 17
hospitalization (17) 17
multivariate analysis (17) 17
medical research (16) 16
retrospective studies (16) 16
therapy (16) 16
confidence intervals (15) 15
diagnosis, differential (15) 15
dyspnea (15) 15
heart failure - complications (15) 15
hospitals (15) 15
physiological aspects (15) 15
proportional hazards models (15) 15
acute myocardial-infarction (14) 14
coronary heart disease (14) 14
medical imaging (14) 14
medicine, general & internal (14) 14
prevalence (14) 14
blood pressure (13) 13
chronic disease (13) 13
epidemiology (13) 13
heart attack (13) 13
heart failure - drug therapy (13) 13
medicine, experimental (13) 13
patient outcomes (13) 13
roc curve (13) 13
troponin i - blood (13) 13
usage (13) 13
angina pectoris (12) 12
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of the American College of Cardiology, ISSN 0735-1097, 2011, Volume 58, Issue 18, pp. 1881 - 1889
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 2017, Volume 69, Issue 21, pp. 2646 - 2656
Abstract Recently, treatment with 2 newer classes of type 2 diabetes drugs were found to reduce events in patients with diabetes and cardiovascular (CV)... 
Cardiovascular | Internal Medicine | blood glucose | cardiovascular disease | heart failure | outcomes | hypoglycemic agents | CARDIAC & CARDIOVASCULAR SYSTEMS | EVENTS | MYOCARDIAL-INFARCTION | SAFETY | HEART-FAILURE | SECONDARY ANALYSIS | RISK | MELLITUS | GLUCOSE | ROSIGLITAZONE | Cardiovascular Diseases - complications | Diabetes Mellitus, Type 2 - blood | Survival Rate - trends | Global Health | Cardiovascular Diseases - prevention & control | Humans | Risk Factors | Cardiovascular Diseases - mortality | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Diabetes Mellitus, Type 2 - complications | Hypoglycemic Agents - pharmacology | Heart failure | Type 2 diabetes | Diabetics | Peptides | Mortality | Glycosylated hemoglobin | Glucose | Heart attack | Dextrose | Cardiac patients | Hypoglycemic agents | Research institutes | Drug therapy | Cardiology | Diabetes therapy | Myocardial infarction | Heart | Glucagon | Cardiovascular disease | Risk factors | Incidence | Urinary bladder | Failure analysis | Blood pressure | Inhibition | Glibenclamide | Cerebral infarction | Abnormalities | FDA approval | Gene expression | Insulin | Body weight gain | Disease prevention | Inhibitors | Biomarkers | Death | Titration | Clinical medicine | Acute coronary syndromes | Health risk assessment | Burns | Cardiovascular diseases | Risk management | Circulation | Kidney transplantation | Drugs | Intervention | Warning | Renal function | Clinical trials | Boundaries | Congestive heart failure | Guidelines | Prevention | Glucose metabolism | Biological effects | Reduction | Calcium-binding protein | Safety | Heart diseases | Age | Stroke | Complications | Diabetes mellitus | Health risks | Tools | Pharmacology | Coronary artery disease | Biological activity | Fractures | Diabetes | Ventricle | Cancer
Journal Article
The American journal of cardiology, ISSN 0002-9149, 2012, Volume 109, Issue 1, pp. 122 - 127
Journal Article
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 2008, Volume 52, Issue 18, pp. 1458 - 1465
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2017, Volume 70, Issue 6, pp. 704 - 712
Abstract Background Sodium glucose co-transporter 2 (SGLT2) inhibitors may reduce cardiovascular and heart failure risk in patients with type 2 diabetes... 
Cardiovascular | Internal Medicine | high-sensitivity troponin | galectin-3 | N-terminal pro–B-type natriuretic peptide | cardiovascular stress | sodium glucose co-transporter 2 inhibitor | soluble ST2 | CARDIAC & CARDIOVASCULAR SYSTEMS | RATIONALE | RISK | MELLITUS | BASE-LINE CHARACTERISTICS | HEART | DISEASE | HYPOTHESIS | PLACEBO-CONTROLLED TRIAL | INHIBITORS | N-terminal pro-B-type natriuretic peptide | EMPAGLIFLOZIN | Hypoglycemic Agents - therapeutic use | Cardiovascular Diseases - etiology | Double-Blind Method | Follow-Up Studies | Humans | Middle Aged | Male | Biomarkers - blood | Troponin I - blood | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - blood | Time Factors | Canagliflozin - therapeutic use | Peptide Fragments - blood | Aged, 80 and over | Cardiovascular Diseases - blood | Female | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Diabetes Mellitus, Type 2 - complications | Natriuretic Peptide, Brain - blood | Type 2 diabetes | Medical research | Analysis | Cardiac patients | Medicine, Experimental | Glucose | Biological markers | Dextrose | Natriuretic peptides | Glucose transporter | Heart failure | Heart | Brain natriuretic peptide | Heart attacks | Peptides | Diabetes mellitus | Health risks | Cardiovascular disease | Galectin-3 | Patients | Troponin | Inhibitors | Troponin I | Sodium | Older people | Calcium-binding protein | Biomarkers | Adults | Diabetes | Cardiovascular diseases | Heart diseases | Age
Journal Article
Journal Article
American Heart Journal, ISSN 0002-8703, 2014, Volume 167, Issue 1, pp. 109 - 115.e2
Journal Article
Journal Article